Tiziana Completes Phase 2a Trial for Intranasal Foralumab in SPMS…

Event summary

Tiziana's Phase 2a INFORM-MS trial for intranasal foralumab in non-active SPMS has completed its last patient visit.
The 12-week trial enrolled 48 patients across three cohorts at multiple U.S. clinical sites.
Topline data from the trial is expected to be announced in October 2026.
An open-label extension phase will follow, offering all participants intranasal foralumab for six months.

The big picture

Tiziana's completion of the Phase 2a INFORM-MS trial marks a critical step in the development of intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for non-active SPMS. This trial is part of a broader push to leverage immunomodulation for neuroinflammatory and neurodegenerative diseases, an area with significant unmet medical needs. The success of this trial could position Tiziana as a key player in the space, particularly if the topline data supports further clinical advancement.

What we're watching

Data Readout: How the topline data in October 2026 will impact the strategic direction of intranasal foralumab.
Regulatory Pathway: Whether the Phase 2a results will support further clinical development or potential regulatory filings.
Competitive Positioning: The pace at which Tiziana can differentiate intranasal foralumab in the SPMS treatment landscape.